Rubedo Life Sciences, founded in 2018 in Sunnyvale, California, develops medicines that target senescent cells, led by RLS-1496. It raised a $40 million Series A in April 2024, and the FDA cleared an IND for an actinic keratosis study in September 2025.
At a glance
| Price from | Custom |
| Best for | Dermatology and senolytics partners |
From Rubedo Life Sciences's own website.
What stands out
- Human data already reported
- Topical drug lowers safety risk
Worth knowing
- Early clinical stage
- Skin conditions first, not systemic ageing
How it ranks
Rubedo Life Sciences is ranked 8th of 10 in Best Longevity Startups (Lister Score 87.7).
#8 in Best Longevity Startups · Lister Score 87.7
Rubedo reported in May 2026 that RLS-1496 cut actinic keratosis lesions by 46% at four weeks in preliminary Phase 1b/2a results..
| Rank | Best Longevity Startups | Score |
|---|---|---|
| 1 | Altos Labs | 96.8 |
| 2 | NewLimit | 95.6 |
| 3 | Retro Biosciences | 94.3 |
| 4 | Loyal | 93.1 |
| 5 | Function Health | 91.8 |
| 6 | Life Biosciences | 90.4 |
| 7 | Juvenescence | 89.1 |
| 8 | Rubedo Life Sciences | 87.7 |
| 9 | Cambrian Bio | 86.4 |
| 10 | Gameto | 85.0 |
Frequently asked questions
How does Rubedo Life Sciences rank on Lister?
Rubedo Life Sciences is ranked 8th of 10 in Best Longevity Startups (Lister Score 87.7).
Appears in
Add this badge to your site
If you work at Rubedo Life Sciences, paste this code into your website to show where it ranks on Lister. The badge links to the ranking and updates within a day when the rank changes.